Stockscreener 앱 받기
22.22
0.94%
-0.21
시간 외 거래:
22.26
0.04
+0.18%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $62 - Moomoo
Cantor Fitzgerald reiterates Overweight on Capricor stock ahead of FDA decision - Investing.com Canada
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus - Sahm
Capricor Sinks After FDA Rejects Drug for Muscle Disease - MSN
Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR - TradingView
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business - Moomoo
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
CAPRCapricor Therapeutics Inc Volatility & Greeks - Finviz
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal - Sahm
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
(CAPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Capricor’s positive 5-year data for DMD treatment comes with a regulatory catch – CAPR stock slides 11% - MSN
July meeting date set for FDA, developer to talk deramiocel for DMD - Muscular Dystrophy News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review - Stocktwits
Securities Class Action Lawsuit Filed Against Capricor Therapeuti - The National Law Review
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock By Investing.com - Investing.com India
Capricor CFO Bergmann sells $732k in shares By Investing.com - Investing.com Australia
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock - Investing.com
Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor Therapeutics Insiders Sold Shares Worth Over $1.5M - TradingView
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell 3000E Index - marketscreener.com
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your - The National Law Review
Capricor Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Litvack Frank - Moomoo
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell Microcap Index - marketscreener.com
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Class Action Alert: Levi & Korsinsky Reminds Capricor (CAPR) Investors of September 15, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shar - The National Law Review
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action - The National Law Review
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting - Intellectia AI
Capricor Therapeutics Announces FDA Advisory Committee Meeting for Deramiocel Cell Therapy in Duchenne Muscular Dystrophy – Minichart - Minichart
Capricor Therapeutics to Face FDA Advisory Panel on BLA for Deramiocel; PDUFA Aug 22 - TradingView
[8-K] CAPRICOR THERAPEUTICS, INC. Reports Material Event - Stock Titan
What's Going On With Capricor Therapeutics Stock On Friday? - Benzinga
Capricor Therapeutics (CAPR) Reports Positive Long-Term Data for Deramiocel - GuruFocus
Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% - Stocktwits
Capricor Therapeutics, Inc. (CAPR) Stock: July FDA Review Tests Deramiocel Outlook - parameter.io
1.17%
2.48%
자본화:
|
볼륨(24시간):